KRTX Annual CFF
$483.37 M
-$372.40 M-43.52%
31 December 2023
Summary:
As of February 1, 2025, KRTX annual cash flow from financing activities is $483.37 million, with the most recent change of -$372.40 million (-43.52%) on December 31, 2023. During the last 3 years, it has risen by +$479.71 million (+13110.52%).KRTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KRTX Quarterly CFF
$19.87 M
+$17.21 M+647.16%
31 December 2023
Summary:
As of February 1, 2025, KRTX quarterly cash flow from financing activities is $19.87 million, with the most recent change of +$17.21 million (+647.16%) on December 31, 2023. Over the past year, it has increased by +$17.21 million (+647.16%).KRTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KRTX TTM CFF
$483.37 M
+$14.48 M+3.09%
31 December 2023
Summary:
As of February 1, 2025, KRTX TTM cash flow from financing activities is $483.37 million, with the most recent change of +$14.48 million (+3.09%) on December 31, 2023. Over the past year, it has increased by +$14.48 million (+3.09%).KRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KRTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.5% | +647.2% | +3.1% |
| 3 y3 years | +10000.0% | +647.2% | +3.1% |
| 5 y5 years | +1652.8% | +647.2% | +3.1% |
KRTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -43.5% | -97.6% | -63.1% |
Karuna Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $483.37 M(-43.5%) | $19.87 M(+647.2%) | $483.37 M(+3.1%) |
| Sept 2023 | - | $2.66 M(-85.5%) | $468.89 M(-64.2%) |
| June 2023 | - | $18.40 M(-95.8%) | $1.31 B(+1.0%) |
| Mar 2023 | - | $442.45 M(+8116.4%) | $1.30 B(+51.6%) |
| Dec 2022 | $855.78 M(+208.3%) | $5.38 M(-99.4%) | $855.78 M(+0.2%) |
| Sept 2022 | - | $844.19 M(>+9900.0%) | $854.14 M(+7879.7%) |
| June 2022 | - | $4.95 M(+293.6%) | $10.70 M(+33.6%) |
| Mar 2022 | - | $1.26 M(-66.5%) | $8.01 M(-97.1%) |
| Dec 2021 | $277.57 M(+7486.1%) | $3.75 M(+400.7%) | $277.57 M(+0.8%) |
| Sept 2021 | - | $749.00 K(-66.8%) | $275.37 M(+0.1%) |
| June 2021 | - | $2.25 M(-99.2%) | $275.15 M(+0.4%) |
| Mar 2021 | - | $270.82 M(>+9900.0%) | $273.96 M(+7387.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $3.66 M(-99.1%) | $1.54 M(+194.3%) | $3.66 M(-98.5%) |
| Sept 2020 | - | $525.00 K(-51.0%) | $236.34 M(-28.4%) |
| June 2020 | - | $1.07 M(+107.4%) | $330.06 M(+0.2%) |
| Mar 2020 | - | $517.00 K(-99.8%) | $329.30 M(-18.7%) |
| Dec 2019 | $405.28 M(+1369.6%) | $234.22 M(+148.5%) | $405.28 M(+133.2%) |
| Sept 2019 | - | $94.24 M(>+9900.0%) | $173.76 M(+78.4%) |
| June 2019 | - | $314.00 K(-99.6%) | $97.39 M(-3.6%) |
| Mar 2019 | - | $76.50 M(+2733.4%) | $101.08 M(+266.5%) |
| Dec 2018 | $27.58 M(+548.9%) | $2.70 M(-84.9%) | $27.58 M(+10.9%) |
| Sept 2018 | - | $17.88 M(+346.9%) | $24.88 M(+255.4%) |
| June 2018 | - | $4.00 M(+33.3%) | $7.00 M(+133.3%) |
| Mar 2018 | - | $3.00 M | $3.00 M |
| Dec 2017 | $4.25 M | - | - |
FAQ
- What is Karuna Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Karuna Therapeutics?
- What is Karuna Therapeutics annual CFF year-on-year change?
- What is Karuna Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Karuna Therapeutics?
- What is Karuna Therapeutics quarterly CFF year-on-year change?
- What is Karuna Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Karuna Therapeutics?
- What is Karuna Therapeutics TTM CFF year-on-year change?
What is Karuna Therapeutics annual cash flow from financing activities?
The current annual CFF of KRTX is $483.37 M
What is the all time high annual CFF for Karuna Therapeutics?
Karuna Therapeutics all-time high annual cash flow from financing activities is $855.78 M
What is Karuna Therapeutics annual CFF year-on-year change?
Over the past year, KRTX annual cash flow from financing activities has changed by -$372.40 M (-43.52%)
What is Karuna Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of KRTX is $19.87 M
What is the all time high quarterly CFF for Karuna Therapeutics?
Karuna Therapeutics all-time high quarterly cash flow from financing activities is $844.19 M
What is Karuna Therapeutics quarterly CFF year-on-year change?
Over the past year, KRTX quarterly cash flow from financing activities has changed by +$17.21 M (+647.16%)
What is Karuna Therapeutics TTM cash flow from financing activities?
The current TTM CFF of KRTX is $483.37 M
What is the all time high TTM CFF for Karuna Therapeutics?
Karuna Therapeutics all-time high TTM cash flow from financing activities is $1.31 B
What is Karuna Therapeutics TTM CFF year-on-year change?
Over the past year, KRTX TTM cash flow from financing activities has changed by +$14.48 M (+3.09%)